<!DOCTYPE html>
<html>
  <head>
    <title>Non-melanoma skin lesions</title>
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta charset="utf-8">
    <!-- Bootstrap -->
    <link href="//netdna.bootstrapcdn.com/bootswatch/3.2.0/flatly/bootstrap.min.css" rel="stylesheet" media="screen">
    <link href="/css/site.css" rel="stylesheet" media="screen">
    <link href="/css/syntax.css" rel="stylesheet" media="screen">

    <!-- HTML5 Shim and Respond.js IE8 support of HTML5 elements and media queries -->
    <!-- WARNING: Respond.js doesn't work if you view the page via file:// -->
    <!--[if lt IE 9]>
      <script src="https://oss.maxcdn.com/libs/html5shiv/3.7.0/html5shiv.js"></script>
      <script src="https://oss.maxcdn.com/libs/respond.js/1.3.0/respond.min.js"></script>
    <![endif]-->
<script>
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
  })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

  ga('create', 'UA-48968311-4', 'jandecaluwe.com');
  ga('send', 'pageview');

</script>
  </head>

  <body>

    <!-- Fixed navbar -->
    <div class="navbar navbar-default navbar-fixed-top">
      <div class="container">
        <div class="navbar-header">
          <button type="button" class="navbar-toggle" data-toggle="collapse" data-target=".navbar-collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </button>
          <a class="navbar-brand" href="/">Rory’s notes</a>
        </div>
        <div class="navbar-collapse collapse">

          <ul class="nav navbar-nav navbar-left">
 
          </ul>

          <ul class="nav navbar-nav navbar-right">
            <li class="active"><a href="/notes/">notes</a></li>
          </ul>

        </div><!--/.nav-collapse -->
      </div>
    </div>


<div class="container">

  <ol class="breadcrumb">
    <li><a href="/">Home</a></li>
      <li><a href="/notes/">notes</a></li>
      <li><a href="/notes/dermatology/">dermatology</a></li>
      <li class="active">Non-melanoma skin lesions</li>
  </ol>

  <div class="page-header">
 
    <h1>Non-melanoma skin lesions</h1>
  </div>

  <div class="row">

    <div class="col-md-3" role="navigation"> 
 
      <div class="sidebar" data-spy="affix" data-offset-top="80" data-offset-bottom="60">
        <div class="well">
          <a href="#"><strong>Non-melanoma skin lesions</strong></a>
          <div class="toc">
<ul>
<li><a href="#first-assess-for-melanoma">First assess for melanoma</a></li>
<li><a href="#solar-keratoses-actinic-keratoses">Solar keratoses (actinic keratoses)</a><ul>
<li><a href="#appearance">appearance</a></li>
<li><a href="#management">Management:</a><ul>
<li><a href="#cryotherapy">Cryotherapy</a></li>
<li><a href="#fluorouracil-5-cream-efudix">Fluorouracil (5%) cream - Efudix</a></li>
<li><a href="#imiquimod-cream-5-aldara-unsubsidised-for-this-indication">Imiquimod cream (5%) - Aldara - unsubsidised for this indication</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="#basal-cell-carcinoma">Basal cell carcinoma</a><ul>
<li><a href="#appearance_1">Appearance:</a></li>
<li><a href="#management_1">Management:</a><ul>
<li><a href="#surgical-excision">Surgical excision</a></li>
<li><a href="#superficial-bcc">Superficial BCC</a><ul>
<li><a href="#cryotherapy_1">Cryotherapy:</a></li>
<li><a href="#imiquimod-subs-under-sa">Imiquimod (subs under SA):</a></li>
<li><a href="#5fu">5FU</a></li>
</ul>
</li>
<li><a href="#gorlins-syndrome">Gorlin’s syndrome:</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="#squamous-cell-carcinoma">Squamous cell carcinoma</a><ul>
<li><a href="#management_2">Management:</a><ul>
<li><a href="#surgical-excision_1">Surgical excision</a></li>
<li><a href="#cryotherapy_2">Cryotherapy</a></li>
<li><a href="#5fu_1">5FU</a></li>
<li><a href="#imiquimod-cream">Imiquimod cream</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="#follow-up">Follow-up</a></li>
<li><a href="#5fu_2">5FU</a></li>
<li><a href="#imiquimod">Imiquimod</a></li>
</ul>
</div>

        </div>
      </div>
    </div>
 
    <div class="content">
      <div class="col-md-6" role="main">
        <blockquote>
<p>1st step is to determine if melanoma</p>
<p>Surgical excision is the first-line treatment for all skin cancer</p>
<ul>
<li>has the highest rate of cure</li>
</ul>
</blockquote>
<ul>
<li>
<p>skin cancer = 80% all NZ cancers (new)/year</p>
</li>
<li>
<p>majority non-melanoma skin cancers</p>
<ul>
<li>
<p>BCC</p>
</li>
<li>
<p>SCC</p>
</li>
</ul>
</li>
<li>
<p>Non-melanoma skin cancers are rarely fatal</p>
<ul>
<li>
<p>grow if not treated early</p>
</li>
<li>
<p>result in substantial destruction of local tissue</p>
</li>
<li>
<p>disfigurement</p>
</li>
</ul>
</li>
<li>
<p>NZ one of highest rates of skin cancer</p>
</li>
<li>
<p>UVR</p>
</li>
<li>
<p>4 risk factors:</p>
<ul>
<li>
<p>increasing age</p>
</li>
<li>
<p>individual patterns of skin exposure</p>
</li>
<li>
<p>skin type and genetic make-up</p>
</li>
<li>
<p>immune system function</p>
</li>
</ul>
</li>
<li>
<p>Male 2:1 die from melanoma</p>
</li>
<li>
<p>outdoor occupation = high contributing factor</p>
</li>
<li>
<p>UVB:</p>
<ul>
<li>damage DNA P53 tumour supressor gene</li>
</ul>
</li>
<li>
<p>UVA:</p>
<ul>
<li>
<p>greater amounts of sunlight</p>
</li>
<li>
<p>penetrates more deeply into skin - longer wavelength</p>
</li>
<li>
<p>pass through glass</p>
</li>
</ul>
</li>
<li>
<p>intermittent high dose sun exposure assoicated with an increased risk of developing melanoma in young adults</p>
<ul>
<li>esp with many melanocytic naevi</li>
</ul>
</li>
<li>
<p>cumulative exposrue - higher with chornic sxposure to sunlight</p>
</li>
<li>
<p>mulitple melanocytic naevi (>100 and more than 5 atypical) = risk factors for melanoma</p>
</li>
<li>
<p>family history: doubles risk</p>
</li>
<li>
<p>inc. rate of skin cancer in people who are immunosuppressed</p>
</li>
</ul>
<h3 id="first-assess-for-melanoma">First assess for melanoma</h3>
<ul>
<li>
<p>ABCDE</p>
</li>
<li>
<p>A: Asymmetry</p>
</li>
<li>
<p>B: Border irregularity</p>
</li>
<li>
<p>C: Colour variation</p>
</li>
<li>
<p>D: Diameter >6mm</p>
</li>
<li>
<p>E: Evolution</p>
</li>
<li>
<p>“How long has it been there?”</p>
<ul>
<li>the lesion has developed and persisited over a period of months then clnical suspicion of cancer increased (melanoma or non-melanoma)</li>
</ul>
</li>
<li>
<p>Have you noticed any changes in size, shape or colour?</p>
<ul>
<li>suggestive of melanoma</li>
</ul>
</li>
<li>
<p>Does this mole look different from others?</p>
<ul>
<li>“ugly duckling”</li>
</ul>
</li>
<li>
<p>Flat/superficial = most common types of melanoma</p>
<ul>
<li>
<p>asymmetrical structure and multiple colours</p>
</li>
<li>
<p>areas of depigmentation are often present</p>
<ul>
<li>indicator of regression</li>
</ul>
</li>
<li>
<p>Amelanotic melanoma = pink</p>
<ul>
<li>small focal point of irregular pigmentation on periphery of lesion</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Nodular melanoma</p>
<ul>
<li>
<p>progressive enlargement, sympoms(pain, bleeding), firma nd raised appearance</p>
<ul>
<li>usually single colour, uniform in shape</li>
</ul>
</li>
<li>
<p>often misdiagnosed</p>
</li>
</ul>
</li>
<li>
<p>Diagnostic excision with narrow margin (2mm)</p>
</li>
<li>
<p>2nd wider excision up to 2cm may bne required</p>
</li>
<li>
<p>Observation for 1-2 months (no more than 3) may be appropriate wiht flat,prigmented lesions where clinical uncertainty</p>
</li>
<li>
<p>\&lt;1mm thick and without histological evidence of mitoses or ulceration considered low-risk of metasisis - can be managed in primary care</p>
</li>
</ul>
<h3 id="solar-keratoses-actinic-keratoses">Solar keratoses (actinic keratoses)</h3>
<ul>
<li>
<p>frequently encountered</p>
<ul>
<li>esp. elderly</li>
</ul>
</li>
<li>
<p>pre-cancerous form of SCC</p>
<ul>
<li><strong>to SCC in up to 16%</strong></li>
</ul>
</li>
<li>
<p>evidence of chornic sun exposure</p>
</li>
</ul>
<h4 id="appearance">appearance</h4>
<ul>
<li>
<p>multiple, pin-red flat spots</p>
</li>
<li>
<p>skin coloured, rough, scaly spots</p>
<ul>
<li>
<p>scale = adherent and difficult to detach</p>
</li>
<li>
<p>if removed: painful bleeding points</p>
</li>
</ul>
</li>
<li>
<p>colour:</p>
<ul>
<li>
<p>skin colorued</p>
</li>
<li>
<p>yellow-brown</p>
</li>
<li>
<p>brown</p>
</li>
<li>
<p>ofter with redddish tinge</p>
</li>
</ul>
</li>
<li>
<p>most \&lt;1cm</p>
</li>
<li>
<p>more easily felt cf. skin</p>
</li>
<li>
<p>80% on head,neck, back of hands/forearms</p>
</li>
<li>
<p>often report tenderness</p>
</li>
<li>
<p>Dermatoscopy:</p>
<ul>
<li>
<p>small, irregular white circles</p>
</li>
<li>
<p>“strawberry” patternL concentric red and white rings</p>
</li>
</ul>
</li>
</ul>
<p>-</p>
<h4 id="management">Management:</h4>
<ul>
<li>
<p>Keratolytic emollients can be applied to provide symptomatic relief</p>
<ul>
<li>Urea cream 10%</li>
</ul>
</li>
<li>
<p>fluorouracil cream more effective long-term > cryotherapy</p>
</li>
<li>
<p>Imiquimod cream tolerated better than fluorouracil</p>
<ul>
<li>better cosmetic results</li>
</ul>
</li>
<li>
<p>If multiple lesions:</p>
<ul>
<li>target thickest/symptomatic with cryotherapy</li>
</ul>
</li>
<li>
<p>Wider areas of ksin with fluorouracil / imiquimod</p>
</li>
<li>
<p>Can be useful to freeeze thicker,tender lesions two to three weeks before starting therapy</p>
</li>
<li>
<p>seborrhoeic keratoses do not respond to topical treatment</p>
</li>
<li>
<p>SPF 50+ sunscreens</p>
</li>
</ul>
<h5 id="cryotherapy">Cryotherapy</h5>
<ul>
<li>
<p>liquid nitrogen 2-5 seconds</p>
</li>
<li>
<p>Repeat in 4 weeks or as necesary</p>
</li>
<li>
<p>can remove 70% of treated solar keratoses</p>
</li>
</ul>
<h5 id="fluorouracil-5-cream-efudix">Fluorouracil (5%) cream - Efudix</h5>
<ul>
<li>
<p>apply od/bd for 2-4 weeks</p>
</li>
<li>
<p>monitor weekly</p>
</li>
</ul>
<h5 id="imiquimod-cream-5-aldara-unsubsidised-for-this-indication">Imiquimod cream (5%) - Aldara - unsubsidised for this indication</h5>
<ul>
<li>
<p>2-3 times/week for 4-6 weeks</p>
</li>
<li>
<p>Assess local response after 3 weeks and adjust treatment frequency if necessary</p>
</li>
<li>
<p>Review again after 4 week treatment-free interval</p>
</li>
<li>
<p>can be repeated</p>
</li>
</ul>
<h3 id="basal-cell-carcinoma">Basal cell carcinoma</h3>
<ul>
<li>
<p>Is the most frequent occuring cancer in humans</p>
</li>
<li>
<p>locally invasive</p>
</li>
<li>
<p>rarely metastasiss</p>
<ul>
<li>\&lt;1%</li>
</ul>
</li>
<li>
<p>almost never fatal</p>
</li>
<li>
<p>personal history of BCC -> inc. risk of devloping melanoma</p>
</li>
<li>
<p>80% face and neck:</p>
<ul>
<li>particularly around eyes and nasolabial fold</li>
</ul>
</li>
</ul>
<h4 id="appearance_1">Appearance:</h4>
<ul>
<li>
<p>“rodent ulcer”</p>
<ul>
<li>raised pearly edges and central atrophy/ulceration</li>
</ul>
</li>
<li>
<p>peraly, shiny nodule with prominent capillary networks = common</p>
<ul>
<li>Telangiectasia</li>
</ul>
</li>
<li>
<p>superifical BCC</p>
<ul>
<li>irregular red, scaly patch/plaque with short linear blood vessels</li>
</ul>
</li>
<li>
<p>Pigmented forms may be observed in people with dark skin / people who tan easily</p>
</li>
<li>
<p>Alow growing over months/years</p>
</li>
<li>
<p>Morphoeic or scleroising BCC may go unnoticed until they are several cm in diameter and penetrated deeply</p>
</li>
<li>
<p>Advanced: large, deep ulcers</p>
</li>
<li>
<p>BCC located near eyes, nose, ear:</p>
<ul>
<li>
<p>invade orbital rim, nasal vault, middle ear</p>
</li>
<li>
<p>may be larger than expected</p>
</li>
</ul>
</li>
<li>
<p>Types:</p>
<ul>
<li>
<p>Nodular (cystic)</p>
<ul>
<li>
<p>most common = face</p>
</li>
<li>
<p>18-40% higher incidence in men</p>
</li>
</ul>
</li>
<li>
<p>Micronodular</p>
</li>
<li>
<p>Superficial</p>
</li>
<li>
<p>Morphoea-form/sclerosing</p>
</li>
<li>
<p>Pigmented</p>
</li>
<li>
<p>Infiltrative</p>
</li>
<li>
<p>Basosquamous</p>
</li>
</ul>
</li>
<li>
<p>Dermatoscopy:</p>
<ul>
<li>
<p>loss of normal skin features and asymmetry of structure and colour</p>
</li>
<li>
<p>microerosions may also be present</p>
</li>
<li>
<p>Pigmentation at edge of lesion in form of irregular light brown,grey,blue</p>
</li>
<li>
<p>blood vessels of BCC branched lines</p>
</li>
<li>
<p>While lines without pigmented network</p>
</li>
</ul>
</li>
</ul>
<h4 id="management_1">Management:</h4>
<h5 id="surgical-excision">Surgical excision</h5>
<ul>
<li>
<p>first line treatment</p>
</li>
<li>
<p>supreior cure rates to topical treatments</p>
</li>
<li>
<p>aggressive, recurrent, or large tumours >6mm on face:</p>
<ul>
<li>Mohs margin-controlled micrographic surgery</li>
</ul>
</li>
<li>
<p>Indications for Mohs:</p>
<ul>
<li>
<p>Recurrent non-melanoma skin cancer</p>
</li>
<li>
<p>Tumours more than 2cm - particularly on high risk body sites</p>
</li>
<li>
<p>Poorly defined clinical margins</p>
</li>
<li>
<p>Aggressive histological subtype - perineural/perivascular involvment</p>
</li>
<li>
<p>Areas where tissue conservation is essential for closure of defect with minimal anatomic distortion</p>
</li>
</ul>
</li>
</ul>
<h5 id="superficial-bcc">Superficial BCC</h5>
<ul>
<li>
<p>may be treated topically</p>
</li>
<li>
<p>punch biopsy may be considered - </p>
<ul>
<li>assess tumour thickness and confirm dx</li>
</ul>
</li>
<li>
<p>Non surgical treatments should not be used if diagnosis of BCC unclear</p>
</li>
</ul>
<h6 id="cryotherapy_1">Cryotherapy:</h6>
<ul>
<li>
<p>freeze-thaw cycles</p>
</li>
<li>
<p>Apply LN for 20-30sec</p>
<ul>
<li>allow to thaw 3-5min</li>
</ul>
</li>
<li>
<p>refreeze</p>
</li>
<li>
<p>unsuitable for facial lesions, due to poor response rates, distal lower limbs</p>
<ul>
<li>persistent ulceration</li>
</ul>
</li>
</ul>
<h6 id="imiquimod-subs-under-sa">Imiquimod (subs under SA):</h6>
<ul>
<li>
<p>confirmed with punch</p>
</li>
<li>
<p>no indicated for: </p>
<ul>
<li>
<p>recurrent</p>
</li>
<li>
<p>invasive</p>
</li>
<li>
<p>infiltrating</p>
</li>
<li>
<p>nodular BCC</p>
</li>
</ul>
</li>
<li>
<p>no evidence cryo vs. imiquimiod</p>
</li>
<li>
<p>Apply to lesion and 1cm beyond OD on 5 days each week for 6 weeks</p>
</li>
<li>
<p>review by at least week 3</p>
</li>
<li>
<p>After 4 week treatment break</p>
<ul>
<li>repeat for further 6 weeks if incomplete</li>
</ul>
</li>
<li>
<p>Can cure 70-80% small superficial BCC</p>
</li>
<li>
<p>Punch to fulfill SA criteria</p>
</li>
<li>
<p>indicated: neck, chest, distal upper limbs</p>
</li>
</ul>
<h6 id="5fu">5FU</h6>
<ul>
<li>
<p>not routinely used</p>
</li>
<li>
<p>apply thinly to affected area bd for 12 weeks</p>
</li>
</ul>
<h5 id="gorlins-syndrome">Gorlin’s syndrome:</h5>
<ul>
<li>
<p>Multiple basal cell carnicoma</p>
</li>
<li>
<p>Pitting of palms and soles</p>
</li>
<li>
<p>Jaw cysts</p>
</li>
<li>
<p>Spine and rib abN</p>
</li>
<li>
<p>Calcification of flax cerebri</p>
</li>
<li>
<p>Cataracts</p>
</li>
<li>
<p>Oral retinoids may help dec. development of BCC in this disorder</p>
</li>
<li>
<p>Albinism also inc. risk of BCC</p>
</li>
</ul>
<h3 id="squamous-cell-carcinoma">Squamous cell carcinoma</h3>
<ul>
<li>
<p>Develop from flat, scale-like (squamous) cells that form outermost layer of epidermis</p>
</li>
<li>
<p>SCC limited to dermis: </p>
<ul>
<li>
<p><strong>intraepidermal carcinoma (IEC)</strong></p>
</li>
<li>
<p>Bowen’s disease no longer used</p>
</li>
</ul>
</li>
<li>
<p>IEC generally flat</p>
<ul>
<li>
<p>several mm in thickenss</p>
</li>
<li>
<p>slow growing months; years</p>
</li>
<li>
<p>Usually multiple irregular orange-red/brown plaques with variable scaling or crusting</p>
</li>
<li>
<p>Dermatoscopy:</p>
<ul>
<li>
<p>light pigmentation in linear array</p>
</li>
<li>
<p>blood vessels appear as groups of irregular large,red dots and coils</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>SCC</p>
<ul>
<li>
<p>tender</p>
</li>
<li>
<p>rarely go unnoticed</p>
</li>
<li>
<p>chronic leg ulcers + HPV infection = inc. risk</p>
</li>
<li>
<p>Chronic leg ulcers may progress into aggressive ulcerating SCC - <em>Marjolin’s ulcer</em></p>
</li>
<li>
<p>Smoking inc. risk of SCC on lip and genetalia</p>
</li>
<li>
<p>SCC also inc risk of melanoma</p>
</li>
<li>
<p>\~80% develop on face and neck</p>
<ul>
<li>other sun exposed places</li>
</ul>
</li>
<li>
<p>Well differentiated:</p>
<ul>
<li>
<p>firm slow growing skin coloured nodules</p>
<ul>
<li>with scaling or a protruding horn</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Less differentiated:</p>
<ul>
<li>
<p>grow more quickly</p>
</li>
<li>
<p>irregular crusted plaque</p>
<ul>
<li>often ulcerated</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Metastasise in \~ 5% of cases</p>
<ul>
<li>
<p>risk higher if lesion large/deep or ear,lip,genitals,mucosal surfaces or involves nerve fibres</p>
</li>
<li>
<p>Also if immune system suppressed</p>
</li>
<li>
<p>Consider regional lympnode exam:</p>
<ul>
<li>
<p>poor differentiation</p>
</li>
<li>
<p>perineural invasion</p>
</li>
<li>
<p>symptoms:</p>
<ul>
<li>pain, burning, stinging, anaesthesia, paraesthesia, facial paralysis, diplopia, blurred vision</li>
</ul>
</li>
</ul>
</li>
<li>
<p>?role of sentinal node biopsy</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Keratoacanthoma</p>
<ul>
<li>
<p>symmetrical nodules</p>
</li>
<li>
<p>central crater or keratin core</p>
</li>
<li>
<p>grow rapidly - diameter of 2cm in a few weeks</p>
</li>
<li>
<p>can cause immune reaction and resolve within months</p>
</li>
<li>
<p>may be indistinguishable from aggressive tumours</p>
</li>
<li>
<p>should be excised</p>
</li>
</ul>
</li>
</ul>
<h4 id="management_2">Management:</h4>
<h5 id="surgical-excision_1">Surgical excision</h5>
<ul>
<li>
<p>first line</p>
</li>
<li>
<p>well differentitated, low risk tumours \&lt;2cm</p>
<ul>
<li>
<p>*<em>4mm margin</em> - sufficient for 95% all primary SCC</p>
</li>
<li>
<p><strong>6mm margin</strong> - or for Mohs</p>
<ul>
<li>
<p>>2cm</p>
</li>
<li>
<p>Classified as moderately or poorly differentiated </p>
</li>
<li>
<p>Extending into subcutaneous tissues</p>
</li>
<li>
<p>ear, lip, scalp, eyelid or nose</p>
</li>
<li>
<p>recurrent</p>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<h5 id="cryotherapy_2">Cryotherapy</h5>
<ul>
<li>
<p>IEC where diameter, location, number make surgery unsuitable</p>
</li>
<li>
<p>single freeze 5-10 sec</p>
</li>
</ul>
<h5 id="5fu_1">5FU</h5>
<ul>
<li>
<p>apply thinly to affected area OD/BD</p>
</li>
<li>
<p>initial duration 8 weeks or longer</p>
</li>
<li>
<p>occlusive dressing - inc. penetration if tisseu reaction is mninimla</p>
</li>
</ul>
<h5 id="imiquimod-cream">Imiquimod cream</h5>
<ul>
<li>
<p>Apply to lesion and 1cm beyond </p>
</li>
<li>
<p>OD on 5 days each week for 6 weeks</p>
</li>
<li>
<p>review 3rd week</p>
</li>
<li>
<p>4 week break treatment may be repeated for another 6 weeks if incomplete resolution</p>
</li>
</ul>
<h3 id="follow-up">Follow-up</h3>
<ul>
<li>
<p>regular self-examination</p>
</li>
<li>
<p>sun smart:</p>
<ul>
<li>
<p>Slip long-sleeved shirt</p>
</li>
<li>
<p>Slop on broad spec sunscreen 15 min prior to going outdoors</p>
</li>
<li>
<p>Slap on hat with wide rim</p>
</li>
<li>
<p>Wrap on pair of wrap-around sunflasses</p>
</li>
</ul>
</li>
<li>
<p>every 6-12 months</p>
</li>
<li>
<p>1/3 - 1/2 develop another malignancy within 5 years</p>
</li>
<li>
<p>SCC 70-80% develop recurrence within this time period</p>
</li>
<li></li>
</ul>
<h3 id="5fu_2">5FU</h3>
<ul>
<li>
<p>toxic to dividing cells</p>
<ul>
<li>
<p>incorporated into DNA nad RNA stopping cell cycle</p>
</li>
<li>
<p>max area = 22cm x 22cm</p>
</li>
</ul>
</li>
<li>
<p>Avoid exposure to sun</p>
<ul>
<li>thus best used during winter</li>
</ul>
</li>
<li>
<p>Hyperkeratotic lesions: </p>
<ul>
<li>covered with occlusive dresisng</li>
</ul>
</li>
<li>
<p>Expected to cause:</p>
<ul>
<li>
<p>local irritation and photosensitivity</p>
</li>
<li>
<p>permanent hyperpigmentation and scarring</p>
</li>
</ul>
</li>
<li>
<p>Erythema multiforme may also occur</p>
</li>
<li>
<p>Inflammation continue for 102 weeks after treatment finished</p>
</li>
<li>
<p>greater inflammatory reaction: more effective treatment</p>
</li>
<li>
<p>pain can be substantial</p>
</li>
<li>
<p>Severe discomfort - treated with topical corticosteroid and analgesia</p>
</li>
<li>
<p>Contraindicated:</p>
<ul>
<li>women who are pregnant or breastfeeding</li>
</ul>
</li>
</ul>
<h3 id="imiquimod">Imiquimod</h3>
<ul>
<li>
<p>immune modifier that causes removal of skin cells by inducing local cytokine production</p>
</li>
<li>
<p>local irration</p>
</li>
<li>
<p>shouldn’t be applied to croken skin</p>
</li>
<li>
<p>packs of 12 sachet</p>
<ul>
<li>each sachet an area of skin up to 25cm2</li>
</ul>
</li>
<li>
<p>well absobed</p>
<ul>
<li>
<p>left on treated area for 7 horus</p>
</li>
<li>
<p>any residue washed off</p>
</li>
</ul>
</li>
<li>
<p>may become inflammed, itchy,ulverated and flaky</p>
</li>
<li>
<p>painful eroisions on mucous membranes</p>
<ul>
<li>> 1cm from eye, nose, lips</li>
</ul>
</li>
<li>
<p>inflammation = effective</p>
</li>
<li>
<p>Steroid cream may reduce treatment efficacy</p>
</li>
<li>
<p>stop = black coloured ulceration or systemic flu-like symptoms</p>
</li>
<li></li>
</ul>
      </div>
    </div>

  </div>
    

    <div class="footer">
        <p>Website powered by <a href="http://urubu.jandecaluwe.com">Urubu</a></p>
    </div>


</div> 


    <!-- jQuery (necessary for Bootstrap's JavaScript plugins) -->
    <script src="https://code.jquery.com/jquery.js"></script>
    <!-- Include all compiled plugins (below), or include individual files as needed -->
    <script src="//netdna.bootstrapcdn.com/bootstrap/3.2.0/js/bootstrap.min.js"></script>

  </body>
</html>
